Taiyen Biotech Co Ltd (1737) - Total Assets

Latest as of June 2026: NT$8.38 Billion TWD ≈ $263.97 Million USD

Based on the latest financial reports, Taiyen Biotech Co Ltd (1737) holds total assets worth NT$8.38 Billion TWD (≈ $263.97 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.

Taiyen Biotech Co Ltd - Total Assets Trend (2003–2025)

This chart illustrates how Taiyen Biotech Co Ltd's total assets have evolved over time, based on quarterly financial data. Also see Taiyen Biotech Co Ltd stock valuation for the company's overall valuation and market capitalisation.

Taiyen Biotech Co Ltd - Asset Composition Analysis

Current Asset Composition (December 2025)

Taiyen Biotech Co Ltd's total assets of NT$8.38 Billion consist of 33.4% current assets and 66.6% non-current assets. Review 1737 total liabilities to assess the company's total debt and financial obligations.

Asset Category	Amount (TWD)	% of Total Assets
Cash & Equivalents	NT$0.00	16.3%
Accounts Receivable	NT$533.71 Million	6.5%
Inventory	NT$376.81 Million	4.6%
Property, Plant & Equipment	NT$0.00	0.0%
Intangible Assets	NT$10.17 Million	0.1%
Goodwill	NT$0.00	0.0%

Asset Composition Trend (2003–2025)

This chart illustrates how Taiyen Biotech Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See 1737 share price today for real-time trading data and today's change.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: Taiyen Biotech Co Ltd's current assets represent 33.4% of total assets in 2025, an increase from 0.0% in 2003.
Cash Position: Cash and equivalents constituted 16.3% of total assets in 2025, up from 1.7% in 2003.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2003.
Asset Diversification: The largest asset category is accounts receivable at 6.5% of total assets.

Taiyen Biotech Co Ltd Competitors by Total Assets

Key competitors of Taiyen Biotech Co Ltd based on total assets are shown below.

Company	Country	Total Assets
Colgate Palmolive (India) Limited NSE:COLPAL	India	Rs30.19 Billion
Guangdong Marubi Biotechnology Co SHG:603983	China	CN¥4.63 Billion
C&S Paper Co Ltd SHE:002511	China	CN¥9.17 Billion
Chongqing Baiya Sanitary Products Co SHE:003006	China	CN¥2.10 Billion
Leifheit Aktiengesellschaft F:LEI	Germany	€185.83 Million
Mcphersons Ltd AU:MCP	Australia	AU$116.49 Million
PENTAL LTD F:81B	Germany	€30.26 Million
Rigolleau SA BA:RIGO	Argentina	AR$154.64 Billion

Taiyen Biotech Co Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	2.48	2.34	2.27
Quick Ratio	2.16	2.05	1.93
Cash Ratio	0.00	0.00	0.00
Working Capital	NT$1.72 Billion	NT$1.69 Billion	NT$2.02 Billion

Taiyen Biotech Co Ltd - Advanced Valuation Insights

This section examines the relationship between Taiyen Biotech Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	0.92
Latest Market Cap to Assets Ratio	0.02
Asset Growth Rate (YoY)	-1.4%
Total Assets	NT$8.26 Billion
Market Capitalization	$192.81 Million USD

Valuation Analysis

Below Book Valuation: The market values Taiyen Biotech Co Ltd's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.

Slight Asset Contraction: Taiyen Biotech Co Ltd's assets decreased by 1.4% over the past year, which may reflect streamlining or optimization of resources.

Annual Total Assets for Taiyen Biotech Co Ltd (2003–2025)

The table below shows the annual total assets of Taiyen Biotech Co Ltd from 2003 to 2025.

Year	Total Assets	Change
2025-12-31	NT$8.26 Billion ≈ $260.32 Million	-1.42%
2024-12-31	NT$8.38 Billion ≈ $264.05 Million	+0.74%
2023-12-31	NT$8.32 Billion ≈ $262.12 Million	+1.32%
2022-12-31	NT$8.21 Billion ≈ $258.71 Million	-3.02%
2021-12-31	NT$8.47 Billion ≈ $266.78 Million	+8.59%
2020-12-31	NT$7.80 Billion ≈ $245.67 Million	+2.58%
2019-12-31	NT$7.60 Billion ≈ $239.49 Million	+3.76%
2018-12-31	NT$7.33 Billion ≈ $230.81 Million	+1.09%
2017-12-31	NT$7.25 Billion ≈ $228.32 Million	+2.75%
2016-12-31	NT$7.05 Billion ≈ $222.22 Million	+2.95%
2015-12-31	NT$6.85 Billion ≈ $215.85 Million	+1.68%
2014-12-31	NT$6.74 Billion ≈ $212.29 Million	+9.18%
2013-12-31	NT$6.17 Billion ≈ $194.43 Million	-10.15%
2012-12-31	NT$6.87 Billion ≈ $216.39 Million	-1.40%
2011-12-31	NT$6.97 Billion ≈ $219.47 Million	+0.22%
2010-12-31	NT$6.95 Billion ≈ $218.98 Million	+0.78%
2009-12-31	NT$6.90 Billion ≈ $217.29 Million	+3.49%
2008-12-31	NT$6.66 Billion ≈ $209.96 Million	-4.79%
2007-12-31	NT$7.00 Billion ≈ $220.53 Million	-6.16%
2006-12-31	NT$7.46 Billion ≈ $235.00 Million	-4.69%
2005-12-31	NT$7.83 Billion ≈ $246.56 Million	-20.45%
2004-12-31	NT$9.84 Billion ≈ $309.93 Million	-14.39%
2003-12-31	NT$11.49 Billion ≈ $362.04 Million	--

About Taiyen Biotech Co Ltd

TW:1737 Taiwan Household & Personal Products

Market Cap

$192.81 Million

NT$6.12 Billion TWD

Market Cap Rank

#16776 Global

#813 in Taiwan

Share Price

NT$30.60

Change (1 day)

+0.33%

52-Week Range

NT$30.40 - NT$32.50

All Time High

NT$37.55